Sign In
Buy IOVA
$4.07
-0.620 (-13.22%)
At Close: Jul 31, 2026
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
10:40am, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
10:05am, Tuesday, 24'th Feb 2026
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
07:00am, Tuesday, 24'th Feb 2026
SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
07:00am, Tuesday, 24'th Feb 2026
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE N
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits
03:15am, Monday, 23'rd Feb 2026
This biotech stock won approval for a cancer treatment a couple of years ago. That treatment is starting to generate revenue growth.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 20'th Feb 2026
SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
04:05pm, Wednesday, 11'th Feb 2026
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of “Hold” from Brokerages
01:44am, Friday, 06'th Feb 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) has received an average rating of "Hold" from the fourteen research firms that are currently covering the firm, MarketBeat.com reports. T
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
05:15pm, Thursday, 05'th Feb 2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 16'th Jan 2026
SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) If you have held Iovance Biotherapeutics, Inc. shares continuously since prior to May 9, 2024, you may have st
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
09:30am, Monday, 29'th Dec 2025
A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.
Iovance Biotherapeutics: Bright Prospects For 2026
12:51am, Monday, 29'th Dec 2025
Iovance Biotherapeutics is reaffirmed as a Buy, driven by Amtagvi's strong efficacy and blockbuster potential in melanoma and lung cancer. IOVA targets significant market expansion, with lung cancer r
Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)
03:17am, Thursday, 25'th Dec 2025
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) are both small-cap medical companies, but which is the better business? We will
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 19'th Dec 2025
SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
